11.25.14
Valeant Pharmaceuticals has received approval from the Food and Drug Administration (FDA) for Onexton Gel (clindamycin phosphate and benzoyl peroxide), 1.2%/3.75%, for the once-daily treatment of comedonal (non-inflammatory) and inflammatory acne in patients 12 and older.
Onexton Gel has a favorable cutaneous tolerability profile and contains no surfactants, alcohol or preservatives, according to Valeant, which will launch the treatment in early 2015.
Onexton is the fourth product to be approved in our medical dermatology business in the past twelve months, three of which were conceived and developed entirely by Valeant's internal R&D team, according to the company.
Onexton Gel has a favorable cutaneous tolerability profile and contains no surfactants, alcohol or preservatives, according to Valeant, which will launch the treatment in early 2015.
Onexton is the fourth product to be approved in our medical dermatology business in the past twelve months, three of which were conceived and developed entirely by Valeant's internal R&D team, according to the company.